Efficacy of the Combination of Ibuprofen and Paracetamol in Acute Non-specific Low Back Pain

NCT ID: NCT05222724

Last Updated: 2023-01-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 176 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-12-01
• Study Completion Date: 2022-10-05

Brief Summary

The aim of the present study is to assess the efficacy and safety of paracetamol/ibuprofen Fixed Dose Combination (FDC) compared to ibuprofen in patients with uncomplicated non-specific acute low back pain after a 3-day treatment period.

Detailed Description

This is a Phase IV, multicenter, international, open-label, parallel-group study.

The study will be conducted at sites located in Italy, Poland and Hungary. The sites will be outpatient facilities and hospitals. A total of 176 patients are planned to be included in the study This trial will be conducted in accordance with the study protocol, GCPs, Declaration of Helsinki (including up-to-date versions) and applicable regulatory requirements.

The present clinical trial aims to evaluate the efficacy and safety of the combination of 2 tablets of paracetamol 500 mg/ibuprofen 150 mg administered 3 times daily, in the management of patients with acute non-specific Low Back Pain (LBP) condition.

Conditions

Low Back Pain

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Tachifene

paracetamol 500 mg/ibuprofen 150 mg FDC, film-coated tablets. Two tablets 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).

Group Type: EXPERIMENTAL

Tachifene

Intervention Type: DRUG

paracetamol 500 mg/ibuprofen 150 mg FDC, film-coated tablets. Two tablets 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).

Brufen

ibuprofen 600 mg, film coated tablets. One tablet 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).

Group Type: ACTIVE_COMPARATOR

Brufen

Intervention Type: DRUG

ibuprofen 600 mg, film coated tablets. One tablet 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).

Interventions

Tachifene

paracetamol 500 mg/ibuprofen 150 mg FDC, film-coated tablets. Two tablets 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).

Intervention Type: DRUG

Brufen

ibuprofen 600 mg, film coated tablets. One tablet 3 times daily for 3 days (i.e., every 8 hours ± 1 hour).

Intervention Type: DRUG

Other Intervention Names

paracetamol 500 mg/ibuprofen 150 mg; ibuprofen 600 mg

Eligibility Criteria

Inclusion Criteria

• Male and female patients of any ethnic origin between 18 and 64 years of age (limits included).
• Patients with uncomplicated and localized acute low back pain or acute exacerbation of chronic low back pain (not radiating below the gluteal fold), with moderate/severe pain at baseline. Minimum VAS score ≥ 40 mm at screening visit.
• Women of childbearing potential and women with no menses for a period < 12 months must have a negative pregnancy test at Visit 0 and have to agree not to start a pregnancy from the signature of the informed consent up to the Final Visit/Visit 2, using an appropriate birth control method such as combined oestrogen-progestin containing hormonal contraceptives (e.g., oral, injectable, transdermal), progestin-only hormonal contraceptives (e.g., oral, injectable, implantable), intrauterine device (IUD) or Intrauterine hormone-releasing System (IUS) in combination with male condom, bilateral tubal occlusion, vasectomised partner, sexual abstinence. The following definitions will be considered:

• Woman of childbearing potential (WOCBP): i.e., fertile, following menarche and until becoming post-menopausal, unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.
• A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.
• Patients legally capable of giving their consent to participate in the study and available to sign and date the written informed consent.

Exclusion Criteria

• Known hypersensitivity or allergy to the active ingredients and/or to any component of the study medications.
• Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption
• Lactating and pregnant women.
• Clinically significant abnormalities on physical examination, vital signs or laboratory tests at Visit 0 which in the opinion of the Investigator could interfere with the study procedures or endpoints evaluation.
• Suspicious or confirmed COVID-19 infection at time of screening visit.
• History of cervical, thoracic, or lumbosacral pain for ≥75% of the time in the last year, or of any other Low Back Pain episode in the last 3 months that required pharmacological treatment with an opioid analgesic.
• Patients with:

• serious spinal pathology; spinal surgery in the year prior to screening or history of more than one spinal surgery; history of severe lumbar spinal stenosis; ankylosing spondylitis; lumbosciatalgia; herniated disc or radiculopathy; severe arthritis and osteoporosis; muscular diseases, such as myositis, poliomyelitis, muscular dystrophy and myotonia; fibromyalgia; myasthenia grave; fracture or recent history of violent trauma of the back; structural deformity of the back;
• history of hypersensitivity to aspirin or any other non-steroidal anti-inflammatory drugs; suspicion of inflammatory, infective or neoplastic cause of pain; non- specific back symptoms related to abdominal, pelvic or thoracic pathology sensory and/or motor deficits in lower extremities;
• history of gastroduodenal ulcer or bleeding;
• history of severe cardiac, hepatic or renal insufficiency;
• current anticoagulant therapy;
• previous treatment with anticoagulants in the seven days before the screening visit;
• concomitant use of physical or alternative therapies to treat current episode of pain;
• local steroid injection for any reasons within previous 30 days;
• alcohol or drug-addition or abuse;
• cancer, not in remission or in remission less than 1 year;
• active influenza or other viral syndrome; immunosuppression; systematically unwell; unexplained significant weight loss;
• widespread neurological symptoms (including cauda equina syndrome) or any brain disease; ever suffered from any brain damage or have been in a coma; epilepsy or seizure;
• active or suspected oesophageal, gastric, pyloric channel, or duodenal ulceration, or bleeding in the last 30 days;
• blood-formation disturbance;
• renal and/or hepatic failure;
• acute hepatitis;
• acetylsalicylic acid-triggered asthma;
• history of asthma;
• glucose-6-phosphate dehydrogenase-deficient patients; glutathione deficiency, dehydration, chronic malnutrition; anaemia.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 64 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

TFS Trial Form Support

INDUSTRY

Sponsor Role: collaborator

Aziende Chimiche Riunite Angelini Francesco S.p.A

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Università degli Studi della Campania "Luigi Vanvitelli"

Caserta, CE, Italy

Azienda Ospedaliera Universitaria Policlinico G.Rodolico

Catania, , Italy

Azienda Ospedaliera Universitaria Integrata di Verona

Verona, , Italy

In-Vivo sp z o. o.

Bydgoszcz, , Poland

Przychodnia "Przy Szapitalu"

Bydgoszcz, , Poland

Zespół Porani Specjalistycznych Reumed Filia nr 1 Wallenroda

Lublin, , Poland

Centrum Medyczne Pratia Poznan

Skorzewo, , Poland

Nasz Lekarz Przychodnie Medyczne

Torun, , Poland

Centrum Medyczne AstiMed

Warsaw, , Poland

Centrum Medyczne PRATIA

Warsaw, , Poland

Centrum Medyczne Reuma Park

Warsaw, , Poland

Countries

Italy; Poland

Other Identifiers

2020-005278-86

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

147(Z)WO20157

Identifier Type: -

Identifier Source: org_study_id